Core Viewpoint - The company ST HuLuWa (605199.SH) is facing multiple challenges including expected performance losses, new product approvals, regulatory investigations, and share freezes of its controlling shareholder [1] Group 1: Performance Outlook - The company anticipates a net loss attributable to shareholders in 2025, estimated between -210 million and -310 million yuan, primarily due to industry policy adjustments, market environment changes, increased depreciation from new production facilities, and rising financial costs [2] Group 2: Product Development - The company's wholly-owned subsidiary has received approval from the National Medical Products Administration for the registration of "Compound Polyethylene Glycol Electrolyte Oral Solution," aimed at treating chronic constipation and fecal impaction. Additionally, the company has obtained registration for "Ebastine Oral Solution." These new product approvals are expected to enhance the company's product line, although future sales performance remains uncertain due to policy and market factors [3] Group 3: Regulatory Issues - The company and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, with the investigation ongoing. The company faces risks of investor lawsuits due to prior disclosure issues. Following a negative audit opinion on internal controls for the 2024 financial report, the company's stock has been subject to risk warnings (ST) since April 30, 2025. The company has established a special rectification team to address internal control issues [4] Group 4: Shareholder Pledge - A portion of shares held by the controlling shareholder, Hainan HuLuWa Investment Development Co., Ltd., has been judicially frozen, accounting for 5.97% of the total share capital, which may introduce uncertainties regarding the stability of the company's control [5]